12/10/2023 0 Comments Cimzia copay card![]() Grade 3 or 4 increased amylase/lipase occurred in 7% and 1.9% of patients, respectively. Increased amylase/lipase occurred in 14% of patients treated with TABRECTA in GEOMETRY mono-1. Elevations in amylase and lipase levels have occurred in patients treated with TABRECTA. Based on the severity of the adverse reaction, withhold, reduce dose, or permanently discontinue TABRECTA. Monitor liver function tests (including ALT, AST, and total bilirubin) prior to the start of TABRECTA, every 2 weeks during the first 3 months of treatment, then once a month or as clinically indicated, with more frequent testing in patients who develop increased transaminases or bilirubin. Three patients (0.8%) discontinued TABRECTA due to increased ALT/AST. Grade 3 or 4 increased ALT/AST occurred in 7% of patients. Increased alanine aminotransferase (ALT)/aspartate aminotransferase (AST) occurred in 15% of patients treated with TABRECTA in GEOMETRY mono-1. Hepatotoxicity occurred in patients treated with TABRECTA. Immediately withhold TABRECTA in patients with suspected ILD/pneumonitis and permanently discontinue if no other potential causes of ILD/ pneumonitis are identified. Monitor for new or worsening pulmonary symptoms indicative of ILD/pneumonitis (eg, dyspnea, cough, fever). Nine patients (2.4%) discontinued TABRECTA due to ILD/pneumonitis. ![]() ILD/pneumonitis occurred in 4.8% of patients treated with TABRECTA in the GEOMETRY mono-1 study, with 1.9% of patients experiencing grade 3 ILD/pneumonitis and 1 patient experiencing death (0.3%). ILD/pneumonitis, which can be fatal, occurred in patients treated with TABRECTA. Interstitial Lung Disease (ILD)/Pneumonitis.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |